bill hemmer, good morning, partner. dana: i m dana perino and this is america s newsroom. we made it to february. bill: we did. dana: a little long month that one of january. defense secretary lloyd austin will hold a news conference later this morning. anticipates building for his first major address since his secretive hospital stay. he is expected to face questions on many issues, not least his health. bill: payback against iran. what form does it come? questions swirling about the size and timing of the u.s. response after the deaths of three american soldiers and the wounding of dozens of others by an iranian proxy group out of iraq. all this with another group expanding their targets from the red sea to the air. dana: jennifer griffin is live at the pentagon to set it up for us this morning. you will have a front row seat this morning. we will. dana, this is the first time that the press has had an opportunity to question defense secretary lloyd austin abo
in a statement, joe biden called it another unprecedented step in taking away basic freedoms from women and putting their health at risk. adding, if it stands, it would prevent women in every state from accessing the medication, regardless of whether abortion is legal in a state. earlier thejustice department had also announced that it will be appealing the court s decision and will look into separate ruling out of washington state. that ruling is seperate and contradictory to the one in texas, but was handed down about the same time. in a partialand preliminary injunction, the washington judge prohibited the fda from immediately pulling the drug off shelves. let s take a closer look at the medication. the drug, mifepristone, is a medicinal pill which can be taken at home. it s used in more than half of us pregnancy terminations, and was first approved for use more than 20 years ago in 2000. live now to mary ziegler, professor of law at uc davis in california. we know now
Love Island USA Season 6 Cast: Meet the New Islanders stylecaster.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from stylecaster.com Daily Mail and Mail on Sunday newspapers.
Sidoti reiterated their neutral rating on shares of Surmodics (NASDAQ:SRDX – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. The brokerage currently has a $43.00 target price on the stock. SRDX has been the topic of a number of other reports. Needham & Company LLC reaffirmed a hold rating on […]